Top Page
Alterity Therapeutics
(OTC:ATH)
Alterity Therapeutics (ATH) vs. iShares MSCI Australia ETF (EWA)
Alterity Therapeutics Business Overview & Revenue Model
Alterity Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.44M | 5.44M | 4.02M | 3.92M | 5.12M | 4.34M |
| Gross Profit | 5.31M | 5.31M | 3.80M | 3.63M | 4.76M | 3.98M |
| EBITDA | -14.63M | -14.63M | -22.95M | -17.51M | -17.39M | -19.36M |
| Net Income | -12.15M | -12.15M | -19.12M | -13.81M | -12.85M | -15.31M |
Balance Sheet | ||||||
| Total Assets | 46.03M | 46.03M | 19.22M | 27.32M | 41.36M | 33.59M |
| Cash, Cash Equivalents and Short-Term Investments | 40.66M | 40.66M | 12.64M | 15.77M | 34.81M | 28.12M |
| Total Debt | 155.46K | 155.46K | 159.04K | 210.38K | 117.49K | 65.65K |
| Total Liabilities | 3.62M | 3.62M | 5.43M | 4.50M | 5.89M | 3.12M |
| Stockholders Equity | 42.40M | 42.40M | 13.80M | 22.81M | 35.47M | 30.47M |
Cash Flow | ||||||
| Free Cash Flow | -10.71M | -11.45M | -12.61M | -20.04M | -12.43M | -17.34M |
| Operating Cash Flow | -10.71M | -11.45M | -12.61M | -20.04M | -12.34M | -17.33M |
| Investing Cash Flow | -7.50M | -7.50M | -5.72K | -36.46K | -89.15K | -10.47K |
| Financing Cash Flow | 25.54M | 39.67M | 9.22M | 124.34K | 16.30M | 36.69M |
Alterity Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | AU$150.95M | 21.95 | 27.24% | 1.25% | 0.65% | -9.90% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | AU$119.63M | ― | -42.68% | ― | ― | 63.46% | |
| ― | AU$121.46M | ― | ― | ― | ― | 0.66% | |
| ― | $107.98M | ― | -83.09% | ― | ― | 55.94% | |
| ― | $179.99M | ― | -81.03% | ― | -20.79% | 73.98% | |
| ― | AU$107.88M | -13.24 | -47.98% | ― | 700.00% | 26.88% |
Alterity Therapeutics Corporate Events
Alterity Therapeutics Limited has announced its Annual General Meeting scheduled for November 21, 2025, at Deloitte Australia’s offices in Melbourne. The company emphasizes the importance of shareholders submitting proxy forms and questions in advance to facilitate a well-prepared meeting. This announcement highlights Alterity’s commitment to transparent communication with its stakeholders and adherence to new provisions under the Corporations Act.
Alterity Therapeutics announced that data from its ATH434-201 Phase 2 clinical trial will be presented at the 2025 International Congress of Parkinson’s Disease and Movement Disorders. The trial results showed that ATH434 significantly improved clinical outcomes in MSA patients, demonstrating robust efficacy and safety, and has been granted Fast Track and Orphan Drug Designations by the FDA and European Commission. This development positions Alterity as a key player in the neurodegenerative disease treatment market, potentially offering the first-ever treatment for MSA.
Alterity Therapeutics has released a new commercial assessment for its lead drug candidate ATH434, aimed at treating Multiple System Atrophy (MSA), estimating potential global peak sales at USD $2.4 billion. The assessment, based on positive Phase 2 trial results, indicates strong interest from neurologists, with over 70% likely to prescribe ATH434 due to its efficacy in slowing disease progression and stabilizing symptoms, positioning Alterity favorably in the neurodegenerative treatment market.
Alterity Therapeutics has announced a change in the director’s interest notice, specifically regarding Brian Meltzer’s holdings. The notice reveals that there was a disposal of 7,000,000 unlisted options expiring on September 17, 2025, at $0.09, with no consideration involved. This change in holdings may impact the company’s stock dynamics and reflects ongoing adjustments in its governance and financial strategies.
Alterity Therapeutics Limited announced the cessation of 35 million securities due to the expiry of options without exercise or conversion as of September 17, 2025. This cessation may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategy and future growth prospects.
Alterity Therapeutics presented data from their Phase 2 clinical trial of ATH434 at the American Neurological Association Annual Meeting, showing the drug’s efficacy in slowing disease progression in Multiple System Atrophy (MSA) and its favorable safety profile. The trial demonstrated significant improvements in disease severity and motor performance, reinforcing ATH434’s potential as a disease-modifying therapy and generating optimism in the medical community.
Alterity Therapeutics has announced the issuance of over 1.6 billion fully paid ordinary shares, as per the regulations of the Corporations Act. This move is part of the company’s strategy to raise capital without the need for disclosure under Part 6D.2 of the Corporations Act, indicating compliance with necessary legal provisions and transparency requirements, which may impact its financial positioning and stakeholder confidence.
Alterity Therapeutics Limited announced the quotation of 1,666,666,663 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of September 15, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s financial flexibility and market presence, which could have implications for its strategic initiatives and stakeholder interests.
Alterity Therapeutics Limited announced a proposed issue of 1,666,666,663 ordinary fully paid securities, with the issue date set for September 15, 2025. This move is part of a placement or other type of issue, potentially impacting the company’s financial standing and market position by increasing its capital base, which may support ongoing research and development efforts.
Alterity Therapeutics has successfully raised A$20.0 million through a strategic placement of shares to international and Australian investors, strengthening its financial position. This funding will support the continued development of ATH434, a treatment for Multiple System Atrophy, and enhance the company’s clinical and regulatory strategies, positioning it for potential strategic partnerships.
Alterity Therapeutics announced the filing of its Annual Report on Form 20-F with the SEC, including audited financial statements for the year ending June 30, 2025. This filing, along with the XBRL interactive data, is available on their website, reflecting the company’s commitment to transparency and regulatory compliance, which could bolster stakeholder confidence and enhance its industry positioning.
Alterity Therapeutics announced that its CEO, David Stamler, will present a corporate update at the Biotech Showcase. This presentation highlights the company’s progress, particularly the positive data from its ATH434 trials for Multiple System Atrophy, potentially strengthening its position in the neurodegenerative disease treatment market.
Alterity Therapeutics Limited has released its Corporate Governance Statement for the financial year ending 2025, detailing its adherence to the ASX Corporate Governance Council’s principles. The company has implemented a comprehensive Corporate Governance Plan, including a Board Charter that defines the roles and responsibilities of its board members and management. This announcement underscores Alterity’s commitment to transparency and accountability, potentially strengthening its position in the industry and enhancing stakeholder confidence.
Alterity Therapeutics Ltd has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles, demonstrating its commitment to transparency and accountability in management and oversight. This release is significant for stakeholders as it reflects Alterity’s dedication to maintaining high governance standards, which can enhance investor confidence and potentially impact its market positioning positively.
Alterity Therapeutics reported a 66.3% increase in revenue for the year ending June 30, 2025, reaching A$446,291, primarily from interest received. Despite a net loss of A$12,147,828, the company improved its financial position with a significant cash increase to A$33,158,642. This financial performance highlights Alterity’s ongoing commitment to its core activities without significant changes, although no dividends were declared for the year.
Alterity Therapeutics Limited has announced the quotation of 1,283,942 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of August 22, 2025. This move reflects the company’s ongoing efforts to strengthen its financial position and enhance its market presence, potentially impacting its operational capabilities and offering new opportunities for investors.
Alterity Therapeutics Limited announced the issuance of 312,400,200 unlisted options set to expire on August 8, 2030, with an exercise price of US$0.0086. This move, part of an employee incentive scheme, reflects the company’s strategic efforts to align employee interests with long-term growth and stability, potentially enhancing its market position and stakeholder value.
Alterity Therapeutics Limited has announced the issuance of 11,500,000 unlisted options, set to expire on August 8, 2030, with an exercise price of $0.013. This issuance, part of an employee incentive scheme, reflects the company’s efforts to align employee interests with long-term strategic goals, potentially enhancing its competitive positioning in the biotechnology sector.
Alterity Therapeutics recently announced the publication of a significant neuroimaging measure from its bioMUSE Natural History Study in the Annals of Clinical and Translational Neurology. This measure, known as the MSA Atrophy Index, serves as an imaging marker for diagnosing and tracking the progression of Multiple System Atrophy. The announcement was marked as market-sensitive, as it coincided with a slight increase in the company’s stock price, reflecting its potential impact on Alterity’s market positioning and stakeholder interests.
Alterity Therapeutics has released a corporate presentation that includes forward-looking statements. These statements, as per US Securities Laws, involve risks and uncertainties that could cause actual results to differ materially from expectations, highlighting the importance of understanding the associated risk factors.
Alterity Therapeutics has received U.S. FDA Fast Track Designation for its investigational drug ATH434, aimed at treating Multiple System Atrophy (MSA), a neurodegenerative disease with no approved therapies. This designation, along with positive results from Phase 2 clinical trials, highlights the potential of ATH434 to slow disease progression and improve symptoms, reinforcing the company’s confidence in its MSA program as it prepares for further interactions with the FDA.
Alterity Therapeutics announced positive topline results from its open-label Phase 2 clinical trial of ATH434 in patients with multiple system atrophy (MSA). The trial demonstrated that ATH434 provides clinical benefits by stabilizing neurological symptoms and slowing brain atrophy, with a favorable safety profile. These findings are consistent with previous studies and support the advancement of ATH434 as a potential treatment for MSA, a disease currently lacking modifying medications. The results are promising for stakeholders, indicating potential progress in addressing this challenging condition.
Alterity Therapeutics has announced the publication of a novel MRI endpoint from its bioMUSE Natural History Study in the Annals of Clinical and Translational Neurology. This publication highlights the development of the MSA Atrophy Index, a new neuroimaging measure that uses deep learning to track disease progression in Multiple System Atrophy (MSA) patients. The MSA-AI offers a standardized metric for assessing brain atrophy, which can aid in early diagnosis and improve clinical trial participant selection. The study’s findings underscore the potential of advanced neuroimaging methods to enhance understanding of MSA progression and support the evaluation of disease-modifying therapies.